Updated:
Zhangzhou Pientzehuang Pharmaceutical
Zhangzhou Pientzehuang Pharmaceutical was founded in 1999 as the listed vehicle for a prized state intellectual asset — a classified national formula once...
Zhangzhou Pientzehuang Pharmaceutical
Zhangzhou Pientzehuang Pharmaceutical was founded in 1999 as the listed vehicle for a prized state intellectual asset — a classified national formula once reserved for Ming-dynasty emperors. The firm is 54%-owned by Zhangzhou Jiulongjiang Group, which itself reports to the Zhangzhou State-owned Assets Supervision and Administration Commission. This governance chain places investment decisions under the ultimate oversight of municipal SASAC officials rather than an independent family or founder. The firm's deployment centers on pharmaceutical manufacturing capacity within China, specifically inside its home province of Fujian. It maintains two industrial sites recorded in public filings: a headquarters plant at Hupo Road in Zhangzhou's Xiangcheng District, and a secondary TCM Industrial Garden also in Zhangzhou. Its primary revenue engine — the Pientzehuang hepatoprotective pill — operates under state-mandated pricing power for rare traditional medicine ingredients, including wild musk and natural bezoar. Capital expenditure flows into in-house API production, quality-control infrastructure, and packaging automation rather than external venture positions. The company's investment scale is not publicly disclosed. No external AUM figure exists because Pientzehuang deploys directly from its RMB-denominated balance sheet rather than structured funds. As of May 2026, Altss research confirms the firm lists no named investment professionals beyond SASAC oversight and the Jiulongjiang Group parent. Adjacent vehicles include the two industrial campuses, which function as both production facilities and capital-asset repositories. Pientzehuang's structural differentiator is the inseparability of its investment program from its state-issued pharmaceutical license. Unlike a generic corporate venture arm, every manufacturing deployment directly expands production capacity for a formula the central government declared a Class-1 State Secret in 1993. This means capital allocation doubles as execution of a national medical patrimony mandate — a posture that makes institutional co-investment functionally closed to external limited partners and renders the firm's strategy legible only in the context of provincial industrial policy.
General information
Firm type
Corporate Investor
Year founded
1999
Location
Region
Asia
Country
China
City
Zhangzhou
Corporate office
No. 1 Hupo Road, Xiangcheng District, Zhangzhou, Fujian, China
Principals
Zhangzhou SASAC
Ultimate Controlling Entity
Sector focus
Frequently asked questions
Who exercises ultimate control over Zhangzhou Pientzehuang Pharmaceutical's investment decisions?
Zhangzhou Jiulongjiang Group Co., Ltd. holds a 54% majority equity stake. That entity is itself controlled by the Zhangzhou State-owned Assets Supervision and Administration Commission, which means municipal SASAC officials ultimately direct any material capital-allocation choice at Pientzehuang.
Is Zhangzhou Pientzehuang Pharmaceutical a family office or a corporate venture arm?
It is neither. The firm operates as a state-owned listed company whose investment activity amounts to balance-sheet capital expenditure in its own manufacturing base. There is no external fund, no family wealth pool, and no third-party LP capital reported in public filings.
What does the firm invest in and where?
Deployment concentrates on domestic pharmaceutical manufacturing projects, with recorded facilities at No. 1 Hupo Road in Zhangzhou's Xiangcheng District and a TCM Industrial Garden elsewhere in the same city. Both sites service the firm's own pill production rather than a portfolio of third-party ventures.
Where does Pientzehuang Pharmaceutical's underlying economic value come from?
The firm's principal asset is a traditional Chinese medicine pill for liver conditions, whose formula was granted Class-1 State Secret protection by China's central government in 1993. The exclusivity on that formula — plus restricted access to wild musk and bezoar as raw materials — underwrites the company's pricing power and balance-sheet capacity, which then funds its industrial investments.
Does Zhangzhou Pientzehuang Pharmaceutical accept external co-investors?
No evidence suggests a co-investment program. The firm deploys capital directly from its listed-company balance sheet, with its investment posture reflecting provincial SASAC industrial objectives rather than syndicated GP/LP structures. Institutional allocators seeking managed exposure to China's TCM sector will find this vehicle closed to outside participation.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: